Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

被引：16
|
作者：
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sara A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Lutska, Yana
Bobba, Padma
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter M.
机构：
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-149024
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
79
引用
收藏
页数：9
相关论文
共 50 条
  • [21] Reduction in disease symptoms/impacts after daratumumab, lenalidomide, bortezomib, and dexamethasone treatment for transplant-eligible patients with newly diagnosed multiple myeloma (GRIFFIN study)
    Silbermann, Rebecca
    Laubach, Jacob
    Kaufman, Jonathan
    Sborov, Douglas
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Costa, Luciano
    Anderson, Larry
    Nathwani, Nitya
    Shah, Nina
    Bumma, Naresh
    Costello, Caitlin
    Jakubowiak, Andrzej
    Orlowski, Robert
    Shain, Ken
    Gries, Katharine
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Matt, Kathryn
    Lin, Thomas
    Usmani, Saad
    Voorhees, Peter
    Richardson, Paul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S125 - S126
  • [22] Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with transplant -eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase Ill study (PERSEUS).
    Sonneveld, Pieter
    Broijl, Annemiek
    Gay, Francesca
    Boccadoro, Mario
    Einsele, Hermann
    Blade, Joan
    Dimopoulos, Meletios A.
    Delforge, Michel
    Spencer, Andrew
    Hajek, Roman
    Schjesvold, Fredrik
    Lonergan, Sarah
    Smith, Elena
    Carson, Robin L.
    Crist, Wendy
    Garvin, Wendy S.
    Vermeulen, Jessica
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Real-World Data on the Daratumumab Plus Bortezomib, Thalidomide and Dexamethasone Followed by Lenalidomide Maintenance for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
    Crusoe, Edvan de Queiroz
    Ribeiro, Glaciano
    Moura, Fernanda
    Costa, Abel
    Aranha, Milton
    Bittencourt, Rosane
    Ribeiro, Eduardo
    Neto, Jorge
    Cunha, Rafael
    Mattos, Ederson
    Braga, Walter
    Lima, Juliana Souza
    Gusmao, Breno
    Lopes, Danielle Ovigli
    Berg, Luiza
    Souto, Joao
    Maiolino, Angelo
    Hungria, Vania T. M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S223 - S223
  • [24] Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
    Joseph, Nisha S.
    Kaufman, Jonathan L.
    Dicamillo, Sara
    Roberts, Danielle
    Gupta, Vikas A.
    Hofmeister, Craig C.
    Dhodapkar, Madhav V.
    Boise, Lawrence H.
    Lonial, Sagar
    Nooka, Ajay K.
    BLOOD, 2023, 142
  • [25] Depth of Response to Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone Improves Over Time in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma: Griffin Study Update
    Voorhees, Peter M.
    Kaufman, Jonathan L.
    Laubach, Jacob
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Murphy, Sean
    Lutska, Yana
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    De Boer, Carla
    Hoehn, Daniela
    Lin, Thomas S.
    Richardson, Paul G.
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 127 - 128
  • [26] Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis
    Dimopoulos, Meletios
    Sonneveld, Pieter
    Rodriguez-Otero, Paula
    Hang Quach
    Ho, P. Joy
    Beksac, Meral
    Hulin, Cyrille
    Antonioli, Elisabetta
    Leleu, Xavier
    Mangiacavalli, Silvia
    Perrot, Aurore
    Cavo, Michele
    Belotti, Angelo
    Broijl, Annemiek
    Gay, Francesca
    Mina, Roberto
    Nijhof, Inger S.
    van de Donk, Niels
    Katodritou, Eirini
    Sitthi-Amorn, Anna
    de Boer, Carla J.
    Carson, Robin
    Blade, Joan
    Moreau, Philippe
    Boccadoro, Mario
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S30 - S31
  • [27] Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA
    Sonneveld, Pieter
    Attal, Michel
    Perrot, Aurore
    Hulin, Cyrille
    Caillot, Denis
    Facon, Thierry
    Leleu, Xavier
    Belhadj-Merzoug, Karim
    Karlin, Lionel
    Benboubker, Lofti
    Levin, Mark-David
    Minnema, Monique
    Westerman, Matthijs
    Delforge, Michel
    Zweegman, Sonja
    Pei, Lixia
    de Boer, Carla
    Vanquickelberghe, Veronique
    Kampfenkel, Tobias
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E2 - E3
  • [28] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
    Kazuhito Suzuki
    Nobuhiro Tsukada
    Noriko Nishimura
    Yasuyuki Nagata
    Kiyoshi Okazuka
    Yuko Mishima
    Masahiro Yokoyama
    Kaichi Nishiwaki
    Tadao Ishida
    Shingo Yano
    Yasuhito Terui
    Kenshi Suzuki
    International Journal of Hematology, 2020, 111 : 103 - 111
  • [29] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
    Suzuki, Kazuhito
    Tsukada, Nobuhiro
    Nishimura, Noriko
    Nagata, Yasuyuki
    Okazuka, Kiyoshi
    Mishima, Yuko
    Yokoyama, Masahiro
    Nishiwaki, Kaichi
    Ishida, Tadao
    Yano, Shingo
    Terui, Yasuhito
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (01) : 103 - 111
  • [30] Efscalefect of lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (MM) on CR rates and survival.
    Gleason, Charise
    Nooka, Ajay K.
    Muppidi, Samatha
    Heffner, Leonard T.
    Steuer, Conor E.
    Kumar, Mukesh
    Casbourne, Daniela
    Langston, Amelia A.
    Watson, Melanie
    Boise, Lawrence
    Kaufman, Jonathan L.
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345